ABSTRACT
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in infants, older adults, and patients with weakened immune systems. Disease severity differs by underlying immunologic pathologies, with worse outcomes associated with progression from upper to lower respiratory disease. In this review we address the impact of RSV in immunocompromised populations, and discuss the limited available treatments and the potential impact of newer RSV prevention strategies on immunocompromised adults and children.
- Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
Clicking the link below will connect you to begin the credit-claiming process for CME . After clicking on the link, scroll to the bottom of the page and click on “Complete the CME Process.” You will need your myCME login information to access this.
- Christine E. Koval, MD
- Blanca E. Gonzalez, MD⇑
- Center for Pediatric Infectious Diseases, Cleveland Clinic Children’s Hospital, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- Correspondence:
Blanca E. Gonzalez, MD, Center for Pediatric Infectious Disease, R3, Cleveland Clinic Children’s Hospital, 9500 Euclid Avenue, Cleveland, OH 44195; gonzalb3{at}ccf.org
ABSTRACT
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in infants, older adults, and patients with weakened immune systems. Disease severity differs by underlying immunologic pathologies, with worse outcomes associated with progression from upper to lower respiratory disease. In this review we address the impact of RSV in immunocompromised populations, and discuss the limited available treatments and the potential impact of newer RSV prevention strategies on immunocompromised adults and children.
- Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
